GlassScriptPhysician profile
Ronald Jenkins
NPI 1053312074
$4,669.63
in general payments reported to CMS, 2019-2025
22 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $503 · 2021: $655 · 2022: $1,168 · 2023: $665 · 2024: $409 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $914.84 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $532.04 | 2020-2024 | Trintellix |
| Corium, LLC | $521.86 | 2022-2025 | Azstarys |
| Abbvie INC. | $454.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $430.58 | 2019-2021 | |
| Amgen INC. | $263.58 | 2019-2025 | Evenity |
| Lilly USA, LLC | $216.13 | 2022-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $176.43 | 2019-2020 | |
| Novo Nordisk INC | $149.30 | 2020-2024 | Ozempic, Rybelsus |
| Idorsia Pharmaceuticals US INC | $136.04 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $129.53 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $127.75 | 2022 | |
| Shire North American Group INC | $121.51 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.15 | 2019 | |
| Astellas Pharma US INC | $97.81 | 2022-2023 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.97 | 2020-2022 | |
| Adlon Therapeutics L.P. | $61.07 | 2019-2021 | |
| Eisai INC. | $55.48 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.75 | 2025 | Caplyta |
| Azurity Pharmaceuticals, INC. | $24.53 | 2023 | Edarbi |
| Arbor Pharmaceuticals, INC. | $23.26 | 2019-2021 | |
| Lundbeck LLC | $18.27 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.